183 related articles for article (PubMed ID: 24728078)
1. Increased STAT1 signaling in endocrine-resistant breast cancer.
Huang R; Faratian D; Sims AH; Wilson D; Thomas JS; Harrison DJ; Langdon SP
PLoS One; 2014; 9(4):e94226. PubMed ID: 24728078
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
3. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
[TBL] [Abstract][Full Text] [Related]
4. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
Hou Y; Li X; Li Q; Xu J; Yang H; Xue M; Niu G; Zhuo S; Mu K; Wu G; Li X; Wang H; Zhu J; Zhuang T
J Cell Mol Med; 2018 Dec; 22(12):6077-6086. PubMed ID: 30334368
[TBL] [Abstract][Full Text] [Related]
5. Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signalling axis in breast cancer cells.
Darvin P; Joung YH; Kang DY; Sp N; Byun HJ; Hwang TS; Sasidharakurup H; Lee CH; Cho KH; Park KD; Lee HK; Yang YM
J Cell Mol Med; 2017 Apr; 21(4):720-734. PubMed ID: 27862996
[TBL] [Abstract][Full Text] [Related]
6. The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer.
Gujam FJ; McMillan DC; Edwards J
Oncotarget; 2016 Nov; 7(47):77607-77621. PubMed ID: 27769057
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
8. Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines.
Shim SH; Sung MW; Park SW; Heo DS
Int J Mol Med; 2009 Jun; 23(6):805-10. PubMed ID: 19424608
[TBL] [Abstract][Full Text] [Related]
9. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
Papanikolaou V; Stefanou N; Dubos S; Papathanasiou I; Palianopoulou M; Valiakou V; Tsezou A
Cell Oncol (Dordr); 2015 Apr; 38(2):155-64. PubMed ID: 25539992
[TBL] [Abstract][Full Text] [Related]
10. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
[TBL] [Abstract][Full Text] [Related]
12. STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6.
Galdiero M; Vitiello M; D'Isanto M; Raieta K; Galdiero E
Cytokine; 2006 Dec; 36(5-6):218-28. PubMed ID: 17258468
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Sasidharan Nair V; Toor SM; Ali BR; Elkord E
Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
[TBL] [Abstract][Full Text] [Related]
14. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
Xing J; Li J; Fu L; Gai J; Guan J; Li Q
Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
16. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
17. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
19. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
20. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
Chung SS; Giehl N; Wu Y; Vadgama JV
Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
